Christopher P. Wilding
Impact in
-
- Sarcoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
-
- Vascular Tumors and Angiosarcomas
Papers in
-
- Sarcoma Diagnosis and Treatment 9
- Oncology 5
- Vascular Tumors and Angiosarcomas 2
- COVID-19 and healthcare impacts 1
- Co-authors
- Paul H. Huang (12 shared papers)Robin L. Jones (11 shared papers)Jessica Burns (4 shared papers)Ian Judson (4 shared papers)Lee Jeys (2 shared papers)Michael Parry (1 shared paper)Aik Choon Tan (1 shared paper)Jonathan Young (1 shared paper)
- Journals
- Clinical Cancer Research (1 paper)Journal of Proteomics (1 paper)Current Opinion in Oncology (1 paper)The Journal of Arthroplasty (1 paper)Expert Opinion on Investigational Drugs (1 paper)
- Partner nations
- United KingdomGermanyHong Kong
In The Last Decade
Christopher P. Wilding
16 papers receiving 252 citations
Peers
Comparison fields: 5 of 57
- Pulmonary and Respiratory Medicine 119
- Oncology 80
- Cancer Research 34
- Pathology and Forensic Medicine 23
- Research and Theory 1
Countries citing papers authored by Christopher P. Wilding
This map shows the geographic impact of Christopher P. Wilding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher P. Wilding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher P. Wilding more than expected).
Fields of papers citing papers by Christopher P. Wilding
This network shows the impact of papers produced by Christopher P. Wilding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher P. Wilding. The network helps show where Christopher P. Wilding may publish in the future.
Co-authors
The 25 scholars most cited alongside Christopher P. Wilding, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 48 | |
| 2 | 2016 | 37 | |
| 3 | 2019 | 34 | |
| 4 | 2019 | 25 | |
| 5 | 2020 | 22 | |
| 6 | 2021 | 21 | |
| 7 | 2019 | 16 | |
| 8 | 2020 | 14 | |
| 9 | 2021 | 12 | |
| 10 | 2020 | 6 | |
| 11 | 2024 | 5 | |
| 12 | 2024 | 4 | |
| 13 | 2019 | 3 | |
| 14 | 2022 | 3 | |
| 15 | 2024 | 2 | |
| 16 | A model for family care. | 1988 | 2 |
About Christopher P. Wilding
Christopher P. Wilding is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Surgery, Molecular Biology and Infectious Diseases, having authored 16 papers that have together received 254 indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (9 papers), Vascular Tumors and Angiosarcomas (2 papers), Advanced Proteomics Techniques and Applications (1 paper), Protein Degradation and Inhibitors (1 paper), COVID-19 and healthcare impacts (1 paper), Uterine Myomas and Treatments (1 paper), Lymphoma Diagnosis and Treatment (1 paper) and Histone Deacetylase Inhibitors Research (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (119 citations), Oncology (80 citations), Cancer Research (34 citations), Pathology and Forensic Medicine (23 citations) and Research and Theory (1 citation). Christopher P. Wilding has collaborated with scholars based in United Kingdom, Germany and Hong Kong. Frequent co-authors include Paul H. Huang, Robin L. Jones, Jessica Burns, Ian Judson, Lee Jeys, Michael Parry, Aik Choon Tan, Jonathan Young, Simon Vyse and Andrew Jenks. Their work appears in journals such as Clinical Cancer Research, Journal of Proteomics, Current Opinion in Oncology, The Journal of Arthroplasty and Expert Opinion on Investigational Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.